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Knowledge of the genomic landscape of chronic lymphocytic leukemia (CLL) grows
increasingly detailed, providing challenges in contextualizing the accumulated information. To
define the underlying networks, we here perform a multi-platform molecular characterization.
We identify major subgroups characterized by genomic instability (GI) or activation of
epithelial-mesenchymal-transition (EMT)-like programs, which subdivide into non-
inflammatory and inflammatory subtypes. GI CLL exhibit disruption of genome integrity,
DNA-damage response and are associated with mutagenesis mediated through activation-
induced cytidine deaminase or defective mismatch repair. TP53 wild-type and mutated/
deleted cases constitute a transcriptionally uniform entity in GI CLL and show similarly poor
progression-free survival at relapse. EMT-like CLL exhibit high genomic stability, reduced
benefit from the addition of rituximab and EMT-like differentiation is inhibited by induction of
DNA damage. This work extends the perspective on CLL biology and risk categories in TP53
wild-type CLL. Furthermore, molecular targets identified within each subgroup provide
opportunities for new treatment approaches.
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Characterization of genetic heterogeneity and its relatedclinical impact has provided the fundament for prognosticmodels in chronic lymphocytic leukemia (CLL) and has
been extended considerably in recent years1–3. However, the
context in which genetic alterations arise remains to be further
explored to understand disease dynamics and to refine ther-
apeutic strategies by targeting cellular networks or genetic
dependencies. Alterations of the tumor suppressor genes TP53
and ATM have been identified as major determinants for dys-
functional DNA-damage response (DDR), genomic instability,
selection of genomically complex clones, and poor response to
treatment3–8. Treatment with genotoxic substances was found to
contribute to the inactivation of these tumor suppressors,
acquisition of chromosomal aberrations, and clonal evolution7–10.
However, the mechanisms inducing genomic instability in cases
without such lesions are incompletely characterized. Corre-
spondingly, it remains to be proven if genomic lesions occur
randomly or are specifically selected within a defined molecular
or biologic framework during malignant transformation and over
the natural course of CLL. Other treatment-independent factors
contributing to the selection of alterations may include a het-
erogeneous degree of addiction to environmental stimuli or
necessity to maintain the activity of certain signaling
pathways11,12. Further, genomic lesions may evolve in a narrow
spectrum depending on the related epigenetic makeup13,14.
In this work, we aim to delineate refined biological categories of
CLL and identify cooperating pathogenic mechanisms which facil-
itate distinct pathways or microenvironmental interaction during
disease development and evolution. We address this by performing a
comprehensive characterization incorporating gene expression pro-
files (GEP) from two independent phases III CLL trial cohorts
comprising 726 treatment-naive and relapsed patient samples. Data
from whole-exome sequencing (WES), single-nucleotide poly-
morphism (SNP)-array analysis, and protein expression is included
for detailed biological characterization of the discovery cohort con-
taining samples from untreated CLL patients enrolled on the CLL8
trial15. Discovered biologic subgroups are validated in the inde-
pendent sample set of relapsed patients enrolled onto the REACH
trial16 and then confirmed in vivo using relevant genetically mod-
ified mouse models. Both the CLL8 and REACH trials were con-
ducted as independent pivotal phase III multicenter trials to evaluate
treatment with immunochemotherapy15,16. They, therefore, provide
an ideal basis for the correlation of biological characteristics and
treatment outcome.
Results
Consensus clustering identifies distinct expression signatures
associated with inflammation, genomic instability, and acti-
vation of EMT-like networks. To explore tumor heterogeneity in
CLL, we performed consensus clustering (CC) on CLL8 GEP data
(n= 337, Supplementary Table 1) using 2359 variably expressed
genes corresponding to a standard deviation (SD) of >0.5. First, the
two initial clusters identified for k= 2 and building the most distant
branches of the dendrogram (protocluster C1 and C2) (Supple-
mentary Fig. 1a) were assessed for discriminatory characteristics.
Using gene set enrichment analysis (GSEA), inflammatory features
were identified as most prominent in segregating protocluster C1
and C2 and the subsequently derived clusters. To further decipher
the underlying biology, we performed CC with an increasing
number of clusters (Supplementary Fig. 1a–d) and serial analytical
steps by incorporating additional layers of information as schema-
tically shown (Fig. 1a, Supplementary Fig. 1e). Optimal differentia-
tion of distinct subtypes was achieved for k= 6 GEP clusters
(Fig. 1b, Supplementary Fig. 1e, f), while DNA-based class discovery
approaches were insufficient to uncover similar patterns and the
respective biological context (Supplementary Fig. 1g). Subtypes were
labeled according to the most prominent characteristics (Fig. 1a) as
“genomically instable, non-inflammatory” (GI) for C2 (n= 133),
“genomically instable with inflammatory features” ((I)GI) for C3
(n= 56), “epithelial–mesenchymal-transition-like, non-inflamma-
tory” (EMT-L) for C4 (n= 30) and “epithelial-mesenchymal-tran-
sition-like with inflammatory features” ((I)EMT-L) for C1
(n= 100). C5 cases (n= 11) were labeled as “reprogrammed by
early B cell factor 1” (EBF1-r), identifying tri(12) CLL as a distinct
subtype with strong overexpression of EBF1 and a transcriptional
signature resembling healthy B cells. C6 (n= 7) identified nuclear
receptor-interacting protein 1 (NRIP1) as specific for clusters evol-
ving from the protocluster C1 (Supplementary Fig. 2a). NRIP1 is
associated with clinical outcomes in CLL and is a major regulator of
metabolism and coactivator of NF-kB-dependent inflammation 17.
Cases with TP53 inactivation (Fig. 1b, Supplementary Table 2),
V3-21 usage (Supplementary Table 3), short telomeres (Fig. 1c),
high white blood cell (WBC) counts (Fig. 1d, Supplementary
Table 2), and ZAP-70 positivity (Supplementary Table 3)
(p < 0.05, Fisher’s exact test (two-sided)) were enriched in GI/
(I)GI clusters. TP53 mutated cases without concomitant del(17p)
showed a near-exclusive occurrence in genomically instable cases
(GI/(I)GI: n= 16 (9.5%) vs. EMT-L/(I)EMT-L: n= 1 (0.8%)
(p= 0.002, Fisher’s exact test (two-sided)). GSEA identified
processes associated with genomic instability for GI/(I)GI and
EMT networks for EMT-L/(I)EMT-L (Fig. 2a). Furthermore,
genes involved in the maintenance of genomic stability were
frequently mutated (Supplementary Fig. 2b, c) or overexpressed
(Supplementary Fig. 2d) in the GI/(I)GI cluster.
In summary, CLL can be segregated into two major biological
subgroups defined by genomic instability or EMT-like networks
with variable degrees of inflammatory features, further character-
izing the inflammatory or non-inflammatory subtypes. GI and (I)
EMT-L comprise the two largest and most distinct subtypes. Of
importance, transcriptional homogeneity and consecutive co-
clustering of CLL with GI/(I)GI expression signatures and cases
showing TP53 inactivation indicate that changes in genes other
than TP53may execute similar biological effects and contribute to
genomic instability.
Frequency and distribution of copy number alterations sup-
port a higher susceptibility to DNA damage in genomically
instable CLL. To further investigate genomic instability, we
assessed the distribution of copy number alterations (CNAs)
using SNP-array. Genomic identification of significant targets in
cancer (GISTIC)18 was used to identify significantly altered
regions and candidate genes representing putative targets of focal
chromosomal amplification or loss (Fig. 2b). Both GI and (I)GI
involved frequent gains of 8q24.21 (including MYC) and 2p16.1
(including XPO1, REL). GI further showed gains of 6q22.31 and
losses of 15q15.1 (including KNSTRN, BUB1B), 10q24.3, and
6q21. (I)GI showed losses of 13q14.13. (I)EMT-L had losses for
6q21 and 14q32.1 (Fig. 2b). Although 11q deletions were found in
all clusters at a similar frequency, genes covered on
11q22.1–q22.2 (involving YAP1 and an MMP cluster) were pre-
dicted by GISTIC to be specifically lost in GI (Supplementary
Fig. 2e–g) and showed a confirmatory underexpression (Supple-
mentary Fig. 2h). Assessing the impact of CNAs on expression,
we found cluster-specific profiles of differentially expressed genes
(DEGs) located in and adjacent to the minimally deleted or
minimally gained regions, irrespective of the distribution of single
CNAs (Fig. 2c). This indicates that gene dosage effects for
monoallelic deletions are context-dependent and modulate
dominant pathogenic networks. Context-independent gene
dosage effects were only observed in cases with biallelic deletion
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of 13q14 (Fig. 2d). Significant enrichment and co-occurrence of
deletions involving RB1 (previously defined as type II deletions)19
and losses exceeding cytoband 13q21.1, which we here define as
“long distal breaks” (LDBs), were further observed in GI/(I)GI
(Fig. 2e). Type II deletions compared to type I deletions (not
involving RB1) were significantly enriched in GI/(I)GI (55%) vs.
(I)EMT-L/EMT-L (37.3%) (p= 0.02, Fisher’s exact test (two-
sided)). LDBs involving or exceeding the majority of cytoband
13q21.1 (distal of 54.7 mb) were significantly more frequent in
GI/(I)GI (17.6%) vs. (I)EMT-L/EMT-L (7.1%) (p= 0.03, Fisher’s
exact test (two-sided)). LDBs and type II deletions showed a
significant co-occurrence (87.5%) compared to LDBs and type I
deletions (12.5%) (p < 0.001, one-sample proportions test with
continuity correction) (Fig. 2e).
Taken together, the GI/(I)GI CLL subtype shows increased
genomic complexity and selection of distinct chromosomal aberra-
tions which may contribute to the disruption of genome integrity.
CLL cases with genomic instability show alterations in pro-
cesses protecting genome integrity. Research into genomic
instability in CLL has been primarily focused on functional loss of
TP53 or ATM and the consequent dysfunctional DDR. Con-
versely, here we observed enrichment of DNA repair signatures in
GI/(I)GI (Figs. 2a and 3a–d) and upregulation of ATM and TP53
(Fig. 2c), indicating increased DDR activation. Importantly,
upregulation of p53 and phospho-p53 protein levels was con-
firmed in genomically instable cases without recurrent gene
mutations or chromosomal aberrations other than del(13q)
(Fig. 3e, Supplementary Fig. 3m), confirming a continuous acti-
vation independent of such lesions.
We identified numerous interdependent alterations
increasing genomic instability in GI/(I)GI (summarized in Fig. 3f).
Critical pathogenic events involved telomere erosion (Fig. 1c)
and alterations of the shelterin complex. POT1 mutations
(Supplementary Fig. 2c) are associated with telomeric abnorm-
alities, chromosome breaks or fusions20, and POT1 overexpres-
sion (Supplementary Fig. 2d) implicated an increased
requirement for telomere protection. In addition, BUB1B
and KNSTRN, involved in correct chromosome segregation21,22,
were identified by GISTIC as putative gene targets for
del(15q15.1) (Fig. 2b). We further found alterations of genes
involved in regulating cell cycle checkpoints (Fig. 2d, e,
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Fig. 1 Composition and relationship of CLL subtypes in clustered data. a Schematic representation for analysis, identification of CLL subtypes in the CLL8,
and confirmation in the REACH cohort. The four largest clusters (GI, (I)GI, EMT-L, (I)EMT-L), and associations of NRIP1 with the inflammatory or tri(12)
with the EBF1-r signature were also identified in the independent validation cohort of the REACH trial. Co-clustering of GI/(I)GI and EMT-L/(I)EMT-L cases
in the REACH cohort supports the selection of subgroup-specific characteristics during treatment. b Heatmap showing the consensus clustering for k= 6
used for defining CLL subtypes (n= 337). The distribution of genetic characteristics is shown below the heatmap. Significant enrichment of variables in
clusters is observed for del(17p) (p= 0.05), TP53 mutation (p= 0.01), tri(12) (p= 7e−06), del(13q) (p= 0.03), and IGHV mutation status (p= 0.008)
(all Fisher’s exact test (two-sided)). TP53 frameshift mutations occur exclusively in GI and splice site mutations in EBF1-r cases. Tri(12) is strongly
overrepresented in EBF1-r (72.7%). c Telomere length is significantly different across CLL subtypes (p < 0.001, Kruskal–Wallis test), and shortest length is
observed in GI with a median of 3.8 kb (p= 0.003, Mann–Whitney (two-sided), for GI vs. (I)EMT-L) (n= 333). d White blood cell counts are significantly
different across CLL subtypes (p < 0.0001, Kruskal-Wallis test), show decreased counts in inflammatory CLL and are lowest in (I)EMT-L with median
61.1 G/L (p < 0.0001, Mann–Whitney (two-sided), for GI vs. (I)EMT-L) (n= 330). For Fig. 1a–d, data within individual figures derives from biologically
independent samples. For the boxplots, centerline, box limits, and whiskers represent the median, 25th, and 75th percentiles, and 1.5× interquartile range,
respectively.
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p53 and apoptosis (Figs. 2b, 3h, and 4d, Supplementary Fig. 3a, c,
m). Enrichment of DEGs for specific chromosomal regions
supported complex alterations of tumor suppressors (Supple-
mentary Fig. 3e, f, g). Further, imbalanced MYC networks
(Fig. 3g) involved increased activation (Figs. 2a, b, 3h,
Supplementary Fig. 3b, d, m) or loss of repressors (Figs. 1b and
2b, Supplementary Fig. 2c, d) of MYC family members. In line
with increased genomic instability, we observed a higher
frequency and complexity of chromosomal aberrations in GI
compared to (I)EMT-L cases after genotoxic stress (p= 0.03,
Mann–Whitney (two-sided)) (Fig. 3i).
Signatures of mutational processes highlight the pathogenic
role of DNA repair deficiency and activation-induced cytidine
deaminase in genomically instable CLL. To better characterize
pathogenic processes in CLL subtypes, we analyzed CLL8 cases with
existing WES data (n= 171, CD19 sorted) for mutational processes
in cancer23, referenced in the COSMIC database. Signature projec-
tions revealed strong activation of signature 6 (defective mismatch
repair (MMR), microsatellite unstable tumors), along with other
mutational processes, including signature 3 (defective double-strand
break (DSB)-repair) and 15 (defective MMR, observed in stomach
and lung cancer), in GI (Fig. 3j). Activation of signature 2, attributed
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Fig. 2 Pathway activation and genetic alterations in CLL subtypes. a Heatmap showing overrepresented gene sets (FDR < 0.05) identified through GSEA.
The intensity range of normalized enrichment scores (NES) illustrates the degree of enrichment in CLL subtypes. Gene sets are grouped together according
to the biological context. CLL subtype color code defined in Fig. 2a applies for Fig. 2a–c, e. b GISTIC analysis of copy number alterations (CNA).
Chromosomal positions (1–22) on the y-axis (left) indicate losses (blue, upper panels) or gains (red, lower panels) for major clusters. Affected genes
representing CNA targets within biological networks (such as YAP1) are shown for respective peaks. The most significant chromosomal peaks for major
clusters are indicated on the right of each panel. GISTIC q-values at each locus are plotted from left to right on a log scale (bottom of each panel). Altered
regions with FDR q≤ 0.25 (vertical green line) are considered significant. GISTIC G-Scores (amplitude of the aberration × frequency of its occurrence
across samples) are plotted on top of the panels. c Heatmap showing GEP of genes located within or adjacent to the minimally deleted or minimally gained
regions of recurrent aberrations (n= 337). FDRs for DEGs ((I)EMT-L vs. GI) are highly significant (q < 1e−07). d Heatmap showing GEP of genes located
at/adjacent to the minimally deleted region on 13q (n= 335). The blue color code indicates deletions (dark blue: biallelic; light blue: monoallelic) and the
absence of del(13q) (cyan blue). Genes are ordered corresponding to chromosomal positions for the region between DLEU1 and RB1. e Visualization of
del(13q) per case (blue horizontal lines). y-Axis: cluster color code, x-axis: representative genes and topography for the cumulative coverage of segment
breaks per cluster. A vertical black dotted line indicates the RB1 locus. Vertical red dotted lines indicate the majority of distal losses (around 50–51 mb).
Losses extending to the distal end of cytoband 13q14.3 (orange dotted line) are variably distributed. LDBs involve/exceed the majority of cytoband 13q21.1
(distal of 54.7 mb). Biallelic deletions of 13q14 mostly cover a small region and rarely occur together with larger 13q deletions. For Fig. 2a–e, data within
individual figures derives from biologically independent samples.
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to the activity of APOBEC family members, was increased in (I)GI
compared to GI (p= 0.01, Mann–Whitney (two-sided)) (Fig. 3j,
Supplementary Fig. 3h), irrespective of APOBEC expression (Sup-
plementary Fig. 3l). This suggests that pathogenic deamination pro-
cesses inducing DNA lesions are heterogeneous in genomically
instable CLL. Signature 9 is attributed to the involvement of poly-
merase η in processing activation-induced cytidine deaminase (AID,
encoded by AICDA) mediated cytidine deamination24,25 during
somatic hypermutation (SHM) and was specific for IGHV mutated
cases (p= 2.5e−15, Mann–Whitney (two-sided)) (Fig. 3k, Supple-
mentary Fig. 3i). Signature 9 was higher in GI compared to (I)EMT-L
(p= 0.03, Mann–Whitney (two-sided)) (Supplementary Fig. 3j),
while the distribution of IGHV mutated cases was balanced across
subtypes (GI: 43%, (I)EMT-L: 37%, (I)GI: 36%). Amplifications of
MYC (8q24.21) were most frequently observed in GI/(I)GI cases, in
line with the role of AID and possibly other APOBEC family
members in mediating amplifications and translocations of this
region. Moreover, IGHV mutated cases showed significantly higher
activation of signatures 15 (p= 0.01), 3 and 20 (p < 0.005)
(Mann–Whitney (two-sided)), indicating defective DNA repair
(Fig. 3k). Based on this observation, we considered if the error rate
through defective DNA repair in GI might be exacerbated
in situations of increased AID activity (and the respective AID-
induced mismatches or DSB in non-Ig loci). We observed a trend for
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Fig. 3 Biological processes operative in genomically instable CLL. a–d Heatmap showing expression profiles (n= 337) for genes involved in a mismatch
repair (MMR), b base excision repair (BER), c nucleotide excision repair (NER), d non-homologous end joining (NHEJ). FDRs of DEGs (GI vs. (I)EMT-L) are
indicated (q). Single genes may be involved in multiple processes. e Protein expression in CLL subtypes; p53 (n= 4 each), phospho-p53 (GI/(I)EMT-L:
n= 11 each, (I)GI/EMT-L: n= 8 each) (normalized to actin). f, g Models summarizing alterations which contribute to f genomic instability, g activation of
MYC family members in GI/(I)GI. Source/method (e.g., mRNA/GISTIC) and significance/frequencies are shown in gray, along with estimated mode of
regulation/biological effect (red: increase/activation; blue: decrease/inactivation). h Protein expression in CLL subtypes; PRMT5 (n= 4 each), XPO1/
cMYC (GI/(I)EMT-L: n= 11 each, (I)GI/EMT-L: n= 8 each) (normalized to actin). i Heatmap showing CNAs (paired CLL8 cases; before treatment (pre), at
relapse (post)). CNAs are frequent at relapse (TP53 wild-type: GI/(I)EMT-L; p < 0.05, Wilcoxon signed-rank test (two-sided)). GI cases show more
aberrations (mean) before ((I)EMT-L: 0.83; GI: 1.71) and after treatment ((I)EMT-L: 2.17; GI: 3.43), with considerable increase after treatment when TP53
mutations are included (GI(pre): 1.91, GI(post): 4.36; p < 0.01, Wilcoxon signed-rank test (two-sided)). Arrowheads highlight TP53 inactivation
(preexisting: red; acquired: blue). GI alterations often involve chromosomes other than 13, 12, 11, and 17. j Fraction of signature activations in CLL subtypes
(EBF1-r n= 6, GI n= 68, EMT-L n= 11, (I)EMT-L n= 52, (I)GI n= 31, NRIP1 n= 3) and k activation levels of mutational signatures (median centered) with
order/color code according to clusters and IGHV status (light orange: IGHV mutated, yellow box: GI/(I)GI/(I)EMT-L). IGHV mutated cases show higher
activations for signatures 9, 3, 15, and 20. l Alterations in DNA-damage response genes are more frequent in IGHV mutated GI/(I)GI cases (57%/
50%≥ one alteration) vs. IGHV mutated (I)EMT-L cases (11%≥ one alteration) (p < 0.05, Mann–Whitney (two-sided)). IGHV unmutated cases (either
subtype) have similar frequencies (64–70%≥ one alteration). Only cases with WES for respective genes and known TP53 status (excluding EBF1-r/NRIP1)
were used (n= 156). For Fig. 3a–l, data within individual figures derives from biologically independent samples. For boxplots, centerline, box limits, and
whiskers represent the median, 25th, and 75th percentiles and 1.5× interquartile range, respectively.
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higher activation of DNA damage associated signatures 3 (defective
DSB-repair) and 15 (defective MMR) and significantly higher acti-
vation of signature 6 (defective MMR) (p= 0.02, Mann–Whitney
(two-sided)) in IGHV mutated GI cases compared to IGHV mutated
(I)EMT-L cases, while activations in IGHV unmutated cases of either
subtype were low (Fig. 3k, Supplementary Fig. 3k). Genomic altera-
tions implicated in genomic instability had a significantly lower
incidence in IGHV mutated (I)EMT-L cases compared to IGHV
mutated GI/(I)GI cases (Fig. 3l), which supports a selective vulner-
ability in the context of AID/APOBEC activation and insufficient
MMR. Conversely, when considering IGHV unmutated cases, which
show a high frequency of alterations in genes like TP53, ATM, or
POT1 (Fig. 3l), mutational signatures associated with AID and MMR
deficiency were generally low (Fig. 3k). We subsequently assessed the
impact of AID-mediated induction of genomic instability in vitro
which validated such deleterious effects on the genome (Supple-
mentary Fig. 4a–i).
Together, these data show that distinct subgroups of CLL
exhibit an increased accumulation of genomic lesions in
association with mutational processes indicating deficient DNA
repair and increased AID activity. Our observations indicate that
the identified mutational processes represent independent
pathogenic mechanisms in GI/(I)GI subtypes.
EMT-like differentiation evolves in conjunction with inflam-
mation and genomic stability. As described above, we observed
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Fig. 4 Biological processes operative in CLL with EMT-like networks. a–d Heatmap showing expression profiles (n= 337) for a genes indicating activated
TNFα/NF-kB signaling, b EMT-TFs, c NOTCH target genes (intensity range −1:1), d histone lysine methyltransferases. FDRs of DEGs (GI vs. (I)EMT-L) are
indicated on the right (q). CLL subtype color code defined in Fig. 4a applies for Fig. 4a–d, j–m. e GEP of the CD19 positive (+) and negative (−) compartment from
CLL samples with inflammatory (I) and non-inflammatory (NI) signatures. f GEP of 2374 variably expressed genes for the CD19 negative fraction. g Tumor GEP
indicating activated TNFα/NF-kB signaling and induction of EMT-like programs after BCL1 tumor transplantation. y-axis: median centered expression, x-axis: days
(d) after transplantation of individual samples (p<0.05 shown for d7 vs. d21, Mann–Whitney (two-sided)). hHeatmap showing gene set enrichment, characteristic
for CLL with genomic instability or activation of EMT-like programs, in Eµ-Myc and Eµ-TCL1 mice. Gene sets were identified through GSEA (FDR<0.05) on
proteome profiles of splenic tumor cells from leukemic or terminal Eµ-Myc and Eµ-TCL1 mice (n=4, in two pools) compared with B cells of tumor-free wild-type
mice (n= 12, in two pools). Color-coded normalized enrichment scores (NES) (degree of enrichment; positive: yellow to red; negative: blue, light to dark). Gene sets
are grouped according to the biological context. i Model illustrating biologic characteristics and regulatory interplay of processes in major subgroups (GI and (I)
EMT-L), as specified in respective results sections. j Expression profiles for 2359 variably expressed genes (SD>0.5). Genes with the highest significance (q< 1e
−05) for the EMT-L, EBF1-r, and NRIP1 cluster are indicated. Fold change (FC) is indicated for EBF1-r specific genes (EBF1-r vs. all other). k Piecharts illustrating
global gene expression, percentages indicating over- or under-expression in relation to the median expression per gene across the dataset. l Heatmap showing
genes (n= 69) with strongest differential expression (q≤0.05, FC≥ 2) between the EBF1-r vs. all other clusters. CD19 sorted healthy donor B cells are included
(orange). Arrowheads indicate cases with tri(12). m Agglomerative hierarchical clustering (2359 genes, Pearson complete) for n= 337 CLL and n= 5 healthy
donor B cells (orange). For Fig. 4a–f, h–m, data within individual figures derives from biologically independent samples.
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enrichment of gene sets characteristic for EMT in cases that
showed higher genomic stability (Fig. 2a). During EMT, cells lose
adhesion and gain invasive properties to exit from the sur-
rounding tissue, as found for metastasis. Alterations in the EMT-
like subgroup reflected central hallmarks of EMT such as extra-
cellular matrix remodeling (Supplementary Fig. 5a) and increased
cell motility (Supplementary Fig. 5b).
Transcriptional signatures indicating immune signaling and
TNFα-mediated inflammation were specifically upregulated in
cases with EMT-like networks (Figs. 2a and 4a, Supplementary
Fig. 5c) and correlated with upregulation of NRIP1, a coactivator
of NF-kB-mediated inflammation (Supplementary Fig. 2a).
Besides inflammation, which serves as a strong EMT inducer,
we were able to validate other EMT-inducing alterations like
increased TGF-β signaling (Fig. 2a) and HIF1α upregulation
(Supplementary Fig. 5e) for CLL cases with EMT-like networks.
Overexpression of EMT-associated transcription factors (EMT-
TFs) (e.g., ZEB1, SNAI1, and TWIST1) (Fig. 4b) and receptor
tyrosine kinases (Supplementary Fig. 5d) were further confirma-
tive for induction of EMT-like cellular programs. Notably, EMT-
TFs showed a similar expression in different compartments like
lymph nodes, bone marrow, and peripheral blood (Supplemen-
tary Fig. 5c). We also found overexpression of EZH226 and
SETD727, which may enhance NF-kB- (Fig. 4a) and NOTCH-
(Fig. 4c) mediated EMT, along with other lysine methyltrans-
ferases (Fig. 4d). Inflammatory features were associated with
lower peripheral WBC counts (Fig. 1d) supporting distinct
migratory properties and environmental interaction. Notably,
GEP of the CD19 negative cellular fraction (comprising the
nonmalignant blood component, i.e., monocytes, T and NK cells)
showed unique signatures which reliably discriminated between
patients belonging to the inflammatory/EMT-L or non-inflam-
matory/GI subtype (Fig. 4e, f). These findings, therefore, offer
evidence for a subtype-specific, CLL-mediated impact on
nonmalignant immune cells and altered environmental
interaction.
We further identified several genes in recurrently deleted
regions, including YAP1 and an MMP cluster on 11q22.1–q22.2
(Supplementary Fig. 2e–h) or genes residing in LDB-regions on
13q, like protocadherins (Fig. 2e), which are closely linked with
the EMT process. Since the respective alterations were primarily
observed in genomically instable CLL, the integrity of these
regions seems indispensable for the differentiation towards EMT-
like networks. In conclusion, CLL with EMT-like changes
constitutes a distinct biologic subgroup with a differentiated
impact on the environment.
EMT-like differentiation can be induced in lymphoma and
shows reciprocal inhibition with genomic instability. Since CLL
cases with EMT-like networks show strong transcriptional sig-
natures indicating inflammation and immunological response, we
next aimed to validate the effects of inflammation on EMT-
induction in vivo by utilizing a syngeneic BCL1 lymphoma
transplant mouse model. The BCL1 tumor is a syngeneic lym-
phoma of BALB/c origin and transplantation results in a typical B
cell leukemia/lymphoma characterized by splenomegaly, periph-
eral blood lymphocytosis, and death of all tumor-bearing mice.
This model was used as it reflects major hallmarks of the (I)EMT-
L subtype: (1) lymphoma cells experience strong environmental
stimulus during tumor development and migration to lymphoid
organs and, (2) tumor transplantation itself is associated with a
heavy inflammatory response. Notably, spleen tumor samples
obtained at defined time points after transplantation showed
dynamic GEP changes confirming inflammation and the asso-
ciated induction of EMT-like networks as indicated by
upregulation of Vim, the EMT-TFs Zeb1, Snai1, and down-
regulation of Cdh1, all characteristic of EMT (Fig. 4g).
Regarding the rare occurrence of alterations associated with
genomic instability in cases with EMT-like networks, we next
hypothesized that p53 activation and an increased DDR may
inhibit induction of EMT-like programs. Specifically, (I)EMT-L
cases exhibited low p53 and phospho-p53 levels (Fig. 3e,
Supplementary Fig. 3m), and related pathway activation (Fig. 2a,
c) alongside inverse correlation of TP53 and ZEB1 expression
(Supplementary Fig. 5f). Lymphoma cells showed miR-200c
induction (Supplementary Fig. 5g) while the respective targets,
EMT-TFs ZEB1 and TWIST1, decreased after ionizing radiation
(Supplementary Fig. 5h), in line with the p53-miR-200c-ZEB1
mediated suppression of EMT in solid tumors28. Further,
increased NOTCH signaling (Fig. 4c) may stabilize EMT-like
networks through DDR suppression (Fig. 3a–e), as previously
reported29.
We subsequently aimed to validate the inhibitory effects of
genomic instability on EMT-like differentiation in vivo. Among
the different genes found to be involved in genomically instable
cases, TCL1A and MYC were amplified and/or consistently
upregulated in the GI/(I)GI subgroup and the corresponding
pathway has been identified as a central element for this
pathogenic network (Fig. 3h, Supplementary Fig. 6b). Both genes
represent single oncogenic drivers and their overexpression in
murine models leads to aggressive lymphomas with rapid
proliferation and genomic instability.
With that in mind, we used the two corresponding models: (1)
Eµ-Myc30, where the c-Myc oncogene is placed under the control
of the immunoglobulin enhancer to induce a highly aggressive
B-lymphoid malignancy, and (2) Eµ-TCL131, where the TCL1
oncogene is driven by the immunoglobulin enhancer and
represents a well-established model of CLL. Tumors derived
from these models were specifically assessed for c-Myc- and
TCL1-induced pathway alterations by proteome profiling. Con-
firming the observations made in the human samples, we
identified proteome profiles reflecting network activation
observed for genomically instable cases while processes char-
acteristic for the EMT-like subgroup were downregulated
(Fig. 4h). Alterations leading to genomic instability, therefore
contribute to the inhibition of EMT-like networks.
EMT-transition in vivo was recently found to occur through a
multistep process rather than a binary switch32. We assessed if
such plasticity was present and if the transition to EMT-like
networks could be modulated, in aggressive Eµ-TCL1 tumors,
similar to observations made for the BCL1 model. Generating
strong EMT-inducing stimuli with repetitive cycles of inflamma-
tion and environmental interaction through serial transplanta-
tions (Supplementary Fig. 5i), we were able to mimic EMT
plasticity in Eµ-TCL1 tumor cells (Supplementary Fig. 5j, k).
These findings provide evidence that induction and main-
tenance of EMT-like networks require convergence of strong
EMT-inducing stimuli, while alterations associated with genomic
instability and increasing aggressiveness inhibit EMT-like differ-
entiation as depicted in our model (Fig. 4i).
Pathogenic networks in CLL are not epigenetically controlled
through DNA methylation. Chromatin organization influences
transcriptional activity during differentiated biologic processes, and
altered states can initiate or maintain pathogenic conditions such as
EMT and genomic instability33–36. We observed characteristic
profiles suggesting a heterogeneous transcriptional activity in CLL
subtypes (Fig. 4j, k) supported through distinct patterns of epige-
netic modifiers. These includedMAFG/DNMT3B37 (Supplementary
Fig. 6a, c), TCL1A/DNMT3A38 (Supplementary Fig. 6b, c), TGF-β
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signaling39 (Fig. 2a), histone deacetylases (Supplementary Fig. 6d),
chromodomain–helicase–DNA-binding proteins (Supplementary
Fig. 6e) and others (Supplementary Fig. 6f). We also observed a
stringent association of these genes and the cluster hierarchy, irre-
spective of chromosomal alterations, particularly exemplified for
tri(12) cases. Tri(12) cases exhibited highly distinct transcriptional
profiles forming a single cluster (EBF1-r) or leading to clustered
enrichment in GI and (I)EMT-L (Figs. 1b and 4l, Supplementary
Fig. 6g, h). EBF1 showed the strongest overexpression in EBF1-r
(Fig. 4j) and in agreement with its crucial involvement in the dif-
ferentiation of B cells40, EBF1-r cases stringently clustered with
healthy donor B cells (Fig. 4m).
Notwithstanding such extensive transcriptional reprogram-
ming toward mature B cells, tri(12) cases retained distinct profiles
of epigenetic modifiers reflecting the respective cluster hierarchy
(Supplementary Fig. 6i). To investigate if epigenetic modification
through DNA methylation may contribute to pathogenic network
profiles, we analyzed reduced representation bisulfite sequencing
(RRBS) data for n= 182 matched cases. Robust methylation
differences across groups were not observed (Supplementary
Fig. 6j) for RRBS data. While processes involving AID/APOBEC
family members and BER may actively promote demethylation in
genomically instable cases, we observed significantly higher
expression levels of DNA-demethylases in (I)EMT-L compared
to GI (Supplementary Fig. 6k).
Genomic instability is associated with poor prognosis in CLL.
To define the clinical impact resulting from the underlying
biology of identified CLL subtypes, we assessed the clinical course
in previously untreated patients of the CLL8 trial. Complete and
partial remissions were similar for identified subtypes (Supple-
mentary Tables 4 and 5). Progression-free survival (PFS) was
shortest for chemotherapy treatment in genomically instable cases
but increased considerably when fludarabine and cyclopho-
sphamide (FC) was combined with rituximab (R), with the
strongest overall benefit observed for (I)GI (GI: median PFS
27.8 months (FC) vs. 42.4 months (FCR), HR: 0.55 (95% CI:
0.37–0.82), p= 0.004; (I)GI: median PFS 22.8 months (FC) vs.
68.1 months (FCR), HR: 0.30 (95% CI: 0.15–0.60), p= 0.001)
(Fig. 5a, Supplementary Fig. 7a). In comparison, PFS was con-
siderably longer for FC treatment in (I)EMT-L/EMT-L cases, but
lacked a similar increase in efficacy when rituximab was added
((I)EMT-L: median PFS 36.1 months (FC) vs. 52 months (FCR),
HR: 0.86 (95% CI: 0.53–1.41), p= 0.56; EMT-L: median PFS
45.5 months (FC) vs. 65.2 months (FCR), HR: 0.63 (95% CI:
0.25–1.56), p= 0.31) (Fig. 5a, Supplementary Fig. 7a).
Notably, overall survival (OS) was significantly improved in (I)
GI when FC was combined with rituximab (median OS not
reached (FCR) vs. 56.6 months (FC), HR: 0.32 (95% CI:
0.13–0.79), p= 0.013) (Fig. 5a, Supplementary Fig. 7b).
To further elucidate the clinical impact of the underlying biology,
we performed survival analyses for genetically defined categories. We
first assessed the clinical outcome in subtypes with regard to the
IGHV mutation status. As previously described, identified patterns
for mutational signatures support a selective vulnerability in the
context of AID activation and insufficient MMR in GI/(I)GI cases
(Fig. 3k, l). Confirmatory, IGHV mutated (I)EMT-L cases showed
the longest PFS and OS rates (Fig. 5b, Supplementary Fig. 8). Survival
differences were especially pronounced for FC treatment, showing a
considerably shorter median PFS for IGHV mutated GI cases
compared to IGHV mutated (I)EMT-L cases (29.1 months vs. not
reached, HR: 0.29 (95% CI: 0.11–0.77), p= 0.013), while median PFS
in IGHV mutated GI cases was similar to IGHV unmutated cases of
both the GI and (I)EMT-L subtype (24.4 and 27.8 months)
(Supplementary Fig. 8c, Supplementary Table 6).
Cases with TP53 alterations and wild-type TP53 show a high
transcriptional homogeneity in the GI/(I)GI cluster (Fig. 1b),
reflecting similar biology. We next confirmed that GI compared
to (I)EMT-L cases also show a poorer clinical course when
segregated for chromosomal aberrations or TP53 wild-type status
(Supplementary Fig. 9, 10, Supplementary Table 7). Character-
istics, other than TP53 defect, were homogenously distributed
between both groups (Supplementary Table 2). The prognostic
impact of biological subtypes was further validated in an extended
analysis for molecularly defined subcategories. While alterations
of TP53 and ATM were found to associate with a poor clinical
course, independent of the respective biological subtype, we
observed a strong impact on outcome in TP53 and ATM wild-
type cases and with regard to the SF3B1 mutation status (Fig. 5c,
d). The addition of rituximab considerably improved outcome in
GI, whereas (I)EMT-L cases in contrast consistently lacked a
similar increase of efficacy (Fig. 5a, c, d, Supplementary
Figs. 7–12). In line with imbalanced rates of lethal sepsis
(Supplementary Table 8), representing the fulminant release of
cytokines from the immune system, and distinct expression
profiles for CD19- non-malignant immune cells (Fig. 4f),
differential treatment efficacy for the addition of rituximab
strongly supports a heterogeneous responsiveness of the immune
system in identified biological subgroups.
Validation of CLL subtypes and prognostic impact in the
REACH study cohort. We next validated the major subtypes in
an independent phase III trial cohort of relapsed CLL patients
(REACH, n= 300) and a second internal validation set of pre-
viously unexamined, U-CLL8 samples (n= 89) (Fig. 6a, c, Sup-
plementary Fig. 13a–c, Supplementary Table 9).
REACH was analyzed complementary to CLL8 by using CC on
variably expressed genes with SD > 0.5 (Fig. 6a), which reliably
identified the same biological categories (Fig. 6b, c, Supplementary
Fig. 13a). Subtype-specific expression patterns were also found
when hierarchical clustering was applied on the internal U-CLL8
validation set (Supplementary Fig. 13b). Specific analysis of
expression profiles of genes associated with increased DDR,
alternative mechanisms for p53 inactivation, and distribution of
cases with TP53 defect further validated the CLL subtypes in the
REACH cohort (Supplementary Fig. 13c, Supplementary Table 9).
Increased transcriptional homogeneity and co-clustering of cases
classified as “GI/(I)GI” supported the selection of unifying features
after treatment (Fig. 6a, c, Supplementary Fig. 13c–e). The
prognostic impact remained identical as observed for (I)EMT-L
and GI in CLL8 (Supplementary Fig. 14a, b). As hypothesized from
the biological context, median PFS rates in “GI” cases without TP53
defect resembled those of cases with TP53 defect (19.9 vs.
17.1 months), in contrast to “(I)EMT-L” cases (median PFS
38 months, p < 0.0001) (Fig. 6d). Median OS was shortest for cases
with TP53 defect (35 months), followed by “GI” (68 months,
p < 0.0001) and “(I)EMT-L” (not reached) (Fig. 6e).
Notably, the GI subtype was identified in a multivariate Cox
proportional hazards regression model, along with unmutated
IGHV and del(17p), as an independent adverse prognostic factor
associated with short PFS in relapsed CLL cases (REACH)
(Supplementary Table 10).
Discussion
In this study we identified genetically and clinically distinct CLL
subgroups, comprising genomic instability or activation of EMT-
like networks, extending the current perspective on disease
pathogenesis, progression, and resistance.
While we observed higher leukocyte counts for the CLL8 dis-
covery cohort of CD19 sorted CLL cases, likely through the
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selection of samples with abundant material for multiple analyses,
patient characteristics and especially high-risk markers showed a
well-balanced distribution representative of the full trial
population.
As implied from the identified mutational signatures, genomic
instability may be present before malignant transformation or in
the early phase of the disease and facilitated by defective DNA
repair mechanism and activation of AID during SHM41. Fur-
thermore, AID may be reactivated during the disease course42,43
and add to the acquisition of genomic lesions and clonal evolu-
tion in the GI subtype.
The specific association with the GI/(I)GI subtype further
highlights the role of arginine and lysine methyltransferases in
genomically instable CLL previously found to promote lympho-
magenesis or induce genomic instability in cancer44–48.
While we could not detect differences for promoter or gene
body methylation in identified subgroups, gene-specific regula-
tion of methylation or demethylation dynamics in distinct regions
may still impact pathogenic networks. Our data further support a
broad involvement of other epigenetic modifiers on subtype-
specific chromatin organization, which may impact genomic
stability similar to DNA methylation33–35.
Development of treatment-resistant CLL has been associated
with the inactivation of TP53, ATM, and correspondingly a
deficient DDR3–6. However, here we show rather that genomi-
cally instable CLL exhibit activation but insufficient execution of
DNA-repair programs, irrespective of TP53 status. We have
further classified multiple alterations contributing to genomic
instability into distinct but interdependent processes. These
involve disruption of telomere maintenance, DNA and chromo-
some integrity, altered DDR with insufficient DNA repair, MYC
pathway activation, disrupted cell cycle checkpoints, and chro-
matin organization. Continued execution of these disordered
processes, therefore, maintains genomic instability through the
ongoing accumulation of genomic lesions.
Correspondingly, we show that therapy-associated genotoxic
effects can aggravate genomic instability and worsen long-term
treatment outcomes in such patients when receiving sequential
therapies. In particular, the poor outcome in CLL with wild-type
TP53 and ATM highlights the importance of alternative
mechanisms for the induction of genomic instability. We show
that such cases benefit considerably from p53/DDR-independent
treatments like rituximab, which mediates killing through non-
DDR processes, dependent on Fc and FcγR engagement49.
Contrasting the characteristics observed for GI, we identified
(I)EMT-L cases to exhibit the most distant clustering and com-
prise highly differentiated biology from this subtype. While dif-
ferentiation towards EMT is a well-known phenomenon in
various cancers, EMT-like changes constitute a hitherto unap-
preciated aspect of CLL and were unexpected as metastasis and
the underlying biologic processes seem redundant for leukemic
dissemination. However, EMT-like features and direct
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Fig. 5 CLL subtype, genetic markers, and treatment outcome in CLL8. a PFS (left) and OS (right) according to treatment arm (FC: dotted line; FCR:
continuous line) and subtype (color-coded) (n= 319). CLL subtype color code defined in Fig. 5a applies for Fig. 5a, b. b PFS (left) and OS (right) according
to the IGHV mutation status and subtype (color-coded) (both treatment arms) (n= 310). c PFS according to subtypes; GI (dark blue) and (I)EMT-L (light
blue), TP53, and ATM mutation and/or deletion status (shown for all cases and individual treatment arms) (n= 147). CLL subtype color code defined in
Fig. 5c applies for Fig. 5c, d. d PFS in TP53 wild-type cases according to SF3B1 mutation status for GI (dark blue) or (I)EMT-L (light blue) (n= 193). For
Fig. 5a–d, the log-rank test was used to compare the survival distributions. Data within individual figures derives from biologically independent samples.
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involvement of EMT-TFs were previously reported for patho-
genic processes in hematologic malignancies. These involve reg-
ulation of migratory properties in myeloma50,51, proliferative
capacities and response to treatment in mantle cell lymphoma52
and ALL53, and regulation of immune checkpoints and aggres-
siveness in DLBCL54,55. Higher methylation levels were also
found for the EMT-TF TWIST2 in CLL with mutated IGHV56
and in comparison to healthy donor cells57. Furthermore, EMT-
TFs fulfill crucial roles in normal hematopoiesis and B cell
maturation58.
Since we identify interdependent changes in malignant B cells
which resemble the EMT process we have called this subgroup
and the corresponding specific alterations “EMT-like”. Our
observations do not put lineage-specific and phenotypic changes
recognized in epithelial or mesenchymal tissues during EMT into
focus but categorize cellular properties and processes (e.g.,
inflammatory changes, NOTCH signaling, and genomic stability)
which are found likewise in either tissue context.
The EMT-like subgroup reflects various characteristics of CLL
with increased environmental interaction via receptor or cytokine
signaling and migratory properties59–62. EMT-TFs in CLL,
therefore, may regulate migratory capabilities to infiltrate lym-
phatic tissues or other pro-survival niches, similar to other
cancers32,63,64. Multiple studies have shown the involvement of
cytokines from the microenvironment to regulate tumor inflam-
mation and induction of EMT. Conversely, EMT-TFs themselves
can induce inflammation in cancer cells and shape the micro-
environment accordingly65. EMT-like transcriptional programs
in CLL, therefore, may be activated through inflammatory,
HIF1α, NOTCH1, and other signaling cascades representing a
convergence from multiple pathways during lymphomagenesis.
Stable integration of these signals into activated EMT-like net-
works with a pro-survival advantage may consolidate such
differentiation.
We observed a reduced benefit for rituximab in (I)EMT-L cases
occurring in conjunction with a general NOTCH pathway acti-
vation but independent of NOTCH1 mutations previously asso-
ciated with rituximab resistance3. Systemic effects on nontumor
cells occurring in (I)EMT-L CLL may further elicit functional
disruption of effector cells like macrophages, which execute
treatment effects of rituximab66. In line with our findings, the


































Fig. 6 Validation of CLL subtypes and prognostic impact in the REACH trial cohort. a Consensus heatmap showing the 4 major CLL subtypes identified in
the REACH expression dataset (n= 295); only a few cases (n= 5) segregate in undefined clusters (red/orange). Recurrent alterations are depicted below,
inactivation (del/mut) of TP53 is heterogeneously distributed (“EMT-L”: 11%, “(I)GI”: 16%, “GI”: 20%, “(I)EMT-L”: 9%). b Heatmap depicting characteristic
GEP in CLL8 (major core enrichment gene sets, 931 genes). c Heatmap showing expression of core enrichment gene sets (as used in (b)) for the REACH
dataset. For better comparability, CLL8-complementary clusters (indicated by labels in quotation marks) are ordered in the same order as found by
consensus clustering in CLL8. Increased biologic homogeneity is observed in “GI”/“(I)GI” cases and supported through co-clustering in (a). d PFS in the
REACH dataset for all cases with TP53 defect (yellow), “(I)EMT-L” and “GI” cases without TP53 defect (n= 173). The significance level for GI vs. (I)EMT-L
cases is calculated based on clustering from (a). e OS in the REACH dataset for all cases with TP53 defect (yellow), “(I)EMT-L” and “GI” cases without
TP53 defect (n= 173). For d, e, the log-rank test was used to compare the survival distributions. Data within individual figures derives from biologically
independent samples.
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immunosuppression in solid tumor studies using checkpoint
inhibitors67,68.
We provide experimental evidence from in vivo and in vitro
studies that tumor aggressiveness and the extent of DDR directly
regulate EMT-like networks through suppression of EMT-TFs.
However, EMT-TFs can also act in the reverse direction to sup-
press the DDR. EMT-TFs were shown to downregulate p53 and
diminish its transcriptional activity69–71. Further, expression of
the miR-200 and miR-34 families is regulated by p53 and both
target EMT-TFs28,72–74, which themselves build tight regulatory
loops with these miRs75–77. EMT-TFs protect against DNA
damage in solid tumors, where ZEB1 expression is inversely
correlated with the incidence of CNAs and TP53 mutations78,
which is again mirrored by our data. Such regulatory axes may
strengthen the highly diversified biologic trajectories underlying
the CLL subtypes. As recently reported, EMT-transition in solid
tumors occurs through intermediate hybrid states, which exhibit
distinct cellular properties and show a differentiated interaction
with the microenvironment32. We show that EMT-like differ-
entiation in lymphoma can be modulated, but comprises a dis-
tinct subgroup largely independent of sub-compartments like a
lymph node, bone marrow, or peripheral blood.
In conclusion, this study extends the basis for understanding
CLL pathogenesis and pathway dependencies that may be tar-
geted by novel compounds. Identified molecular targets in a
defined biologic context may further advance the development of
new treatment strategies. Compound combinations targeting, for
example, BCL2 and PRMT5 or XPO1, together with anti-CD20
monoclonal antibodies, may specifically synergize in genomically
instable cases. Future assessment of the subtype-related outcome
in comprehensively characterized trial cohorts testing BCL2-,
BTK- and other inhibitors in development will further elucidate
the therapeutic potential of such treatment combinations.
Methods
Overview for conducted analyses and respective sample size. Specimens were
collected from patients registered on the CLL815 (first-line) and REACH16 (relapse)
trials after informed consent. All patients suffered from progressive disease with the
need for treatment. Samples were CD19 sorted (CLL8 n= 337; REACH, n= 300)
or unsorted (U-CLL8, n= 89). RNA and DNA were purified and assessed for
integrity with routine protocols. Samples were used on the following experimental
platforms: GEP (CLL8, n= 426; REACH, n= 300) on Human Exon 1.0 ST arrays
(Affymetrix), SNP-array analysis (CLL8, n= 309 treatment-naive, of which n= 18
had a paired sample at relapse) on Human SNP Arrays 6.0 (Affymetrix), analysis of
mutations and mutational processes (CLL8, n= 171) using WES (Illumina), RRBS
for methylation analysis (CLL8, n= 182), western blots for validation were per-
formed in selected cases without recurrent alterations. Fluorescence in situ
hybridization (FISH), IGHV, and TP53 mutation analyses were performed upon
trial registration. The multiparameter analysis was conducted for CD19 sorted
CLL8 samples and the distribution of genetic characteristics for analyzed cases was
representative of the full CLL8 trial cohort (Supplementary Table 1). REACH and
U-CLL8 samples were used as validation cohorts. The REACH cohort was chosen
since it was designed complementary to CLL8 and ideally suited to independently
validate identified transcriptional networks and related resistance mechanisms.
U-CLL8 samples were chosen as internal validation set to assess the impact of
lower tumor homogeneity and to exclude the possibility that transcriptional
changes were induced through the process of CD19 sorting. Survival data were
available with a median observation time of 5.9 (CLL8) and 4.9 (REACH) years.
Pathogenic networks were validated using transgenic Eµ-Myc and Eµ-TCL1 mice
or BCL1 and Eµ-TCL1 tumor transplantation models. Details on methods,
demographic and clinical characteristics are also provided in the CONSORT dia-
gram (Fig. 7), sequential workflow and analysis is visualized in Figs. 1a, and 7 and
Supplementary Fig. 1e.
Patients and samples. Analysis was conducted on peripheral blood samples from
previously untreated CLL patients (n= 426) from the CLL8 trial, a prospective,
international, multicenter, open-label, randomized phase 3 study, comparing first-
line treatment with R-FC (n= 408) or FC (n= 409)15. Data on genomic aberra-
tions and mutations, such as del(17p), del(11q), tri(12), del(13q), the IGHV, TP53,
SF3B1, and NOTCH1 mutational status, was included for analysis3. Patient char-
acteristics of target analysis population of n= 337 CD19 sorted CLL used as dis-
covery cohort is provided in Supplementary Table 1. Samples were collected at
enrollment on the CLL8 trial and selected for gene expression profiling based on
availability and RNA quality.
For validation of discoveries, we further used an independent set of GEPs
(n= 300) generated from CD19 sorted CLL patient samples of the REACH study, a
prospective, international, multicenter, open-label, phase 3 study, in which patients
with previously treated CLL were randomized to receive R-FC (n= 276) or FC
alone (n= 276)16. Details on genetic characteristics and other variables for the
CLL8 gene expression cohort are listed in Supplementary Table 1. The primary
objective of the CLL8 and REACH study was to demonstrate superiority with
regards to PFS for R-FC compared with FC alone. The study protocols were
approved by institutional review boards at participating centers, and all patients
gave written informed consent. Details on trial design and eligibility criteria and
clinical outcome have been described elsewhere15,16. The studies were conducted in
accordance with the Declaration of Helsinki. Details for each study are further
provided online at the ClinicalTrials.gov (C T G) homepage. All baseline
parameters including genetics, serum parameters (such as thymidine kinase, β2-
microglobulin), and cell surface/membrane markers (such as ZAP-70) were
performed in a centralized manner in accredited reference laboratories of the
German CLL Study Group (GCLLSG) for the CLL8 trial, as outlined in the original
study protocol. The central GCLLSG genetic reference testing laboratory in Ulm
conducted FISH, mutation analysis of genes recurrently mutated in CLL (such as
TP53, ATM, NOTCH1, and SF3B1) by targeted resequencing and IGHV mutation
status, telomere length, GEP Exon- and SNP-array hybridization and analysis.
Trial participation, genetic testing, and data analysis have been conducted after
informed patient consent, with the approval of the respective local ethics
committees of participating centers. We have complied with all relevant ethical
regulations and data analysis related to this study was approved by the Ulm
University ethics committee.
RNA isolation and quality assessment. Ficoll density gradient centrifugation for
isolation of mononuclear cells was performed on all CLL samples, immunomag-
netic tumor cell enrichment via CD19 (Midi MACS, Miltenyi Biotec, Bergisch
Gladbach, Germany) was performed on (n= 337) samples from the CLL8 trial,
(n= 300) from the REACH trial and (n= 5) healthy donors (2 male, 3 female)
(S1 sample set). Additional 89 samples were left unsorted (S2 sample set). For
n= 10 CLL8 cases both the CD19 positive (+) and negative (−) compartments
from CLL samples with inflammatory and non-inflammatory signatures were
investigated. Only cases where the CD19 negative fraction had <3.30% (median
2.5%) contamination with CD19+ CD5+ cells were used. Total RNA for mRNA
profiling was extracted from whole cell lysate according to the AllPrep DNA/RNA
mini kit (Qiagen). Quality control was assessed using the Agilent 2100 Bioanalyzer
with the RNA 6000 Nano LabChip (Agilent Technologies). The chip was prepared
according to the manufacturer’s protocol and analyzed using the 2100 Expert
software (version 2.6). To ensure the best accuracy and reproducibility samples
with an RNA integrity number (RIN) less than 7.0 were excluded from further
analysis.
Gene expression profiling on human exon 1.0 ST arrays or using quantitative
polymerase chain reaction (qPCR). Samples were analyzed for mRNA expression
using the Affymetrix GeneChip Human Exon 1.0 ST Array (Affymetrix, Santa
Clara, CA, USA). The experiment was conducted according to the manufacturer’s
protocol. In brief, 250 ng RNA per sample was amplified, transcribed to cDNA,
fragmented, and subsequently labeled with biotin. Array hybridization was per-
formed at 45 °C for 16–18 h in the Affymetrix GeneChip Hybridization Oven 640,
arrays were subsequently washed in the Fluidics Station 450 and scanned on the
GeneChip scanner 3000 7G. Complete microarray data sets are available at Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/; GEO accession number:
GSE58211 (REACH only); GSE126595 (full clinical data set); GSE126699
(functional data).
RNA extraction and expression analysis using qPCR: Total RNA was isolated
using RNeasy or DNA/RNA AllPrep mini kit (Qiagen) as per the manufacturer’s
instructions. RNA concentration was estimated using NanoDrop (Thermo
Scientific) and 400 ng of RNA was reverse transcribed using the Reverse
Transcription Kit (Promega). The cDNA was diluted 1:10 prior to addition into the
qPCR reaction mix. Sybr Green Supermix (Bio-rad) was used for the qPCR analysis
as per the manufacturer´s protocol. Fold differences in gene expression were
analyzed using the ΔΔ Ct method by normalizing to control sets as mentioned in
the figure legends. Primers and sequences are provided in Table 1. The expression
level of miR-200c (Cat. No. 002300) was analyzed using the TaqMan™ miRNA
assays from ThermoFisher Scientific, according to the manufacturer’s instruction.
U6 snRNA (Cat. No. 001973) was used as a control. In brief, total RNA was
isolated using the RNeasy kit from Qiagen and 10 ng of the RNA samples were
reverse transcribed using the TaqMan™ MicroRNA Reverse Transcription Kit (Cat.
No. 4366597) according to the manufacturer’s instructions. The reverse-
transcribed cDNA was diluted 1:3 and analyzed using the TaqMan™ Universal PCR
Master Mix, no AmpErase™ UNG (Cat. No. 4364343). The qPCR reaction was
performed in a total volume of 10 µl on a 384-well QuantStudio 5 Real-time PCR
system from ThermoFisher Scientific.
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Normalization of expression data. Raw Affymetrix Human Exon 1.0 ST Array
(HuEx-1_0-st-v2) data files and the data set from Herishanu et al. (GEO ID
GSE21029) have been preprocessed by the robust multichip average (RMA)
algorithm using the aroma.affymetrix R package79 (version 2.12.0). Normalized
data is stored with the assigned analysis ID, raw data files include info on
CD19 selection and code of the CTG registry. Besides RMA normalization,
background correction and quantile normalization were applied. Aroma.affymetrix
was applied to generate gene expression values summarized on the exon/probe set
level and on the transcript level using the “core” probe set definition according to
Affymetrix. “Core” refers to probe sets that are supported by the most reliable
evidence from RefSeq and full-length mRNA GenBank records containing com-
plete CDS information. We further assessed and excluded the presence of potential
batch effects induced by external factors including time point and location of
sampling, duration of storage, and time point of labeling and hybridization. Quality
control was further conducted with relative log expression and normalized
unscaled standard errors, where abnormalities were not observed.
Analysis of expression data. Statistical procedures were performed with the R
software environment, version 3.3.3 and 3.4.1. For GEP analysis BRB-ArrayTools
Version 4.2.1–4.6.1 (available at http://linus.nci.nih.gov/BRB-ArrayTools.html and
www.r-project.org) was used.
Unspecific filtering based on SD > 0.5 was used to select transcripts with the
largest expression variability across all arrays for the CLL8 and REACH gene
expression data set, resulting in 2359 transcripts (mRNA). Agglomerative
hierarchical clustering and CC80 on mRNA were applied using average or complete
linkage and Pearson correlation distance metric with 1000 iterations, respectively.
CC was used to identify the number of clusters with the best clinico-biologic
segregation from k= 2 up to k= 10 possible clusters. The decision in favor of using
k= 6 was based on combined information from the delta area plot, cluster stability,
and clinical or biologic information as previously described. Differential
expression, specifically assessed for genetic variables or defined clusters was
conducted using the Class Comparison Tool from BRB-ArrayTools Version 4.2.1
with univariate permutation tests for individual genes controlling the false
discovery rate (FDR) using the method of Benjamini and Hochberg. Genes for
which the FDR was equal or less than 0.05 were considered significant for
differential expression. Visualizing selected gene sets, such as components of a
defined biological process, was conducted using the Genesis platform81 (release
1.8.0). For depicting the cluster composition of selected gene sets hierarchical
clustering was used with Pearson correlation distance and complete linkage when
needed.
Specific assessment of differential expression for the most common recurrent
alterations including TP53 defect (del(17p) and/or TP53 mutation), del(11q),
tri(12), normal karyotype, del(13q), IGHV status, SF3B1, and NOTCH1 mutations
were analyzed for respective groups defined by the presence of the cytogenetic
alteration or mutation of interest, irrespective of the co-occurrence of other
alterations. If not otherwise detailed, for group-specific assessments focusing on
genetic categories like TP53 defect, the group of interest was calculated against the
reference group containing all other cases.
Identification of biologic processes showing overrepresentation in expression
clusters. GSEA82 was used to discriminate major biologic characteristics and
processes in defined clusters (release v3.0). For the analysis, we used hallmark gene
sets compiled at the Molecular Signatures Database, Broad Institute. GSEA was
applied on mRNA expression data for respective cases of every single cluster in a
comparative fashion with the remaining cases of all other clusters. Overrepresented
gene sets of every single cluster with an FDR q ≤ 0.05, which was used as stringent
filter criteria, were selected for further analysis. Overrepresentation of biologic
processes and resulting pattern composition for all clusters were visualized in a
heatmap using the normalized enrichment scores of the overrepresented gene set as
a measure for the enrichment intensity. Identified biologic processes were grouped
together and labeled according to biologic similarities.
SNP-array analysis. SNP-array analysis on samples from the CLL8 trial for
recurrent CNAs was conducted for n= 309 previously untreated samples of which
n= 18 cases had a paired relapse sample83. All samples had GEP data with the
respective cluster assignment available. In brief, for SNP–Array hybridization
genomic DNA was hybridized to the Genome-Wide Human SNP Array 6.0
according to the manufacturer’s protocol (Affymetrix, Santa Clara, CA, USA). SNP
genotype calls were generated by applying the birdseed algorithm in Genotyping
Console version 4.0 (Affymetrix) using at least 50 arrays in each analysis. DNA
copy number analyses were performed using reference alignment84, dChipSNP85,
and circular binary segmentation86. Segmentation was done pairwise against intra-
individual reference DNA in cases having a pure CD19 negative cell fraction. For
cases lacking matched normal material, the segmentation of each sample was
computed against a pool of ten gender-matched reference samples. Resulting
segments with a window of at least five consecutive markers and mean log2-ratios
of >0.2 and <−0.2 were visually inspected using dChipSNP to exclude inherited
copy number variants and false calls due to experimental artifacts (noise or
interbatch effects). Lesions occurring in a subclone with a clone size under 25%
were revised using the aroma.affymetrix software package87 for an exact deter-
mination of segment boundaries. Size position and location of genes were identified
with the UCSC Genome Browser; assembly March 2006, NCBI36/hg18 (http://
www.genome.ucsc.edu/)88. DNACopy version 1.44.0 and dChip version 2010.01
were used. Microarray raw data contained in the analysis have been made publicly
available at Gene Expression Omnibus (GEO accession number: GSE36908 (CLL8
treatment-naive) and GSE83566 (relapsed)). For visualization of deletion size for
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1) Hallek et al., Lancet. 2010 Oct 2;376(9747):1164-74
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Abbreviations: FC = chemotherapy with fludarabine and cyclophosphamide, FCR = combined chemoimmunotherapy with FC plus rituximab
Fig. 7 CONSORT diagram for the discovery and validation cohort. CONSORT diagram providing information on enrollment and randomization for the
CLL8 and REACH trial, along with details on the selection process of patient specimens used for class discovery and validation by gene expression profiling.
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del(13q) LDBs the Integrative Genomics Viewer89 (release 2.4.16) was used. Total
number of CNAs (including non-recurrent CNAs) occurred with a mean count of
2.1 (range 0–9) per patient and showed homogenous distribution (range 1.7–2.2;
GI: 2.2; EMT-L: 1.9; (I)EMT-L: 2; (I)GI: 1.7).
Genomic identification of significant targets in cancer (GISTIC). To assess the
specific enrichment of genomic amplifications and deletions within clusters iden-
tified by CC of GEP, we applied GISTIC18 (v2.0.23) to the curated SNP-array
dataset. GISTIC identifies significantly amplified and deleted regions across a set of
samples. Each aberration is given a G-score considering its amplitude and the
frequency of its occurrence across samples within a GEP cluster. The significance of
each aberration is estimated by GISTIC comparing the observed G-scores with
results that would be expected by chance, using a permutation test that is based on
the overall pattern of aberrations seen across the genome. To account for multiple
testing, FDR estimation is done providing a consecutive q value for each aberration.
In our analysis, a q-value cut-off below 0.25 was considered to identify significant
results (vertical green line in Fig. 2b).
Longitudinal analysis for CNAs. Longitudinal analysis for acquisition of CNAs
before and after treatment was done on SNP-array data of cases with available
baseline samples at inclusion into CLL8 trial (pre-treatment) and at the time point
of relapse (post-treatment). Paired samples of cases with cluster assignment as
identified through CC on GEP were available for GI baseline (n= 11), GI relapse
(n= 11), (I)EMT-like baseline (n= 7), and (I)EMT-like relapse (n= 7). The
Wilcoxon signed-rank test was applied to test for differences of aberrations in the
pre- and post-treatment setting. Exemplary visualization for large representative
CNAs in individual conditions was performed using dChip.
Mutation analysis and signature projections for mutational processes. Data
were generated on samples from the CLL8 trial cohort. Cases used for this analysis
were available for n= 171 matched cases with corresponding GEP and WES data2.
Matched cases were distributed across identified clusters in representative numbers
(EBF1-r n= 6, GI n= 68, EMT-L n= 11, (I)EMT-L n= 52, (I)GI n= 31, NRIP1
n= 3). Libraries for WES were constructed and sequenced on an Illumina
HiSeq2000 or HiSeq2500 using 76 bp paired-end reads. For targeted sequencing we
used Illumina Design Studio to create custom amplicons with a size of 250 bp
covering all coding regions of TP53 and ATM. Library preparation was performed
using TruSeq Custom Amplicon Assay Kit v1.5 (Illumina, San Diego, CA, USA)
including extension and ligation steps between custom probes and adding of
indices. Samples were pooled and loaded on a MiSeq flowcell in 48 sample batches
and sequenced with MiSeq Reagent Kit 500v2 (Illumina) for a paired-end run.
Median depths of WES and targeted sequencing were 96× and 1332×, respectively.
Software packages for bioinformatic analyses including demultiplexing, alignment
to hg19 reference genome, variant calling, and annotation were used2.
To assess the distribution and respective co-occurrence for enriched pathways
and driver mutations, we used an agglomerative approach to estimate the similarity
of distribution patterns for relative frequencies of mutations per cluster observed in
our dataset, which was done in a hierarchical fashion (average linkage, Pearson
correlation). Subsequently, a detailed representation of the single mutations was
depicted for the respective clusters.
We used non-negative matrix factorization to assess the pathogenic processes
operative in identified CLL subtypes which best explain the mutation pattern
observed in corresponding cases as previously described23. Briefly, we used a fixed
matrix of signatures which were hypothesized to be involved in aging, AID related
DNA damage, and DNA repair deficiencies, as reported by Alexandrov et al.23, to
perform a projection of our data on to these signatures using the nonnegative
matrix factorization multiplicative update as previously described90. After
performing this projection, we used a heuristic approach to perform the signature
selection. We selected the smallest set of signatures which produced a large drop in
the cost function with respect to the signature sets with one more member or the
same number of signatures but a different composition. This heuristic aims to
perform parsimonious signature selection while still accurately representing the
data. The applied SignatureAnalyzer algorithm is available at the Broad Institute
homepage (https://software.broadinstitute.org/cancer/cga/msp).
Protein extraction and western blotting. Cluster-specific validation of protein
expression levels was performed on samples from the respective cluster, not
showing chromosomal aberrations other than del(13q) or gene mutations. For total
protein extraction, cells were lysed in RIPA buffer (150 mM sodium chloride, 1%
IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS),
50 mM Tris pH 8.0) supplemented with 1 mM DTT, 0.5 mM PMSF and phos-
phatase inhibitor cocktail, for 60 min at 4 °C. The amount of protein in each
sample was quantified using the Protein Assay (Bio-rad). Equal concentrations of
proteins were analyzed on 12% polyacrylamide gels or 4–12% Nu-Page pre-cast
gels and subsequently transferred onto polyvinylidene difluoride (PVDF) mem-
branes. The western blot images were acquired using the western gel doc-
umentation system. Antibodies used for western blot analysis in CLL cases not
showing recurrent alterations include the following ones (catalog numbers are
provided in brackets). From Cell Signaling: anti-AKT (#9272), anti-phospho-
AKT(Thr308) (#4056), anti-phospho-p53 (ser15) (#9286), anti-PRMT5 (#2252).
From Abcam: anti-c-Myc (#ab32072), anti-yH2AX (#ab26350), anti-mouse Alexa
Table 1 Primers and TaqMan assays used for validation.
Measurement of candidate genes involved in the EMT process for the serial TCL1A mouse transplant model









Telomere measurement by quantitative PCR adapted from Richard Cawthon, Nucleic Acids Res. 2002 May 15;30(10):e47.
Primer name Species Sequence
Telo std Human 5′-TTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGG 3′
HB std Human 5′-GTCTGTGTGCTGGCCCATCACTTTGGCAAAGAATTCACCCCACCAGTGCAGG CTGCCTATCAGAAAGTGGTGGCTGGTGTGGC-3′
Tel 1b Human 5′-CGG TTT GTT TGG GTT TGG GTT TGG GTT TGG GTT TGG GTT-3′
Tel 2b Human 5′-GGC TTG CCT TAC CCT TAC CCT TAC CCT TAC CCT TAC CCT-3′
HBG3 Human 5′-TGT GCT GGC CCA TCA CTT TG-3′
HBG4 Human 5′-ACC AGC CAC CAC TTT CTG ATA GG-3′
MiR-200c measurement
TaqManTM miRNA assays from ThermoFisher Scientific Species
miR-200c (Cat. No. 002300) Human
U6 snRNA (Cat. No. 001973) Human
AICDA measurement
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Fluor 594 (#ab150116), anti-GAPDH (#ab8245). From Santa Cruz: anti-ERK1 (k-
23) (#sc-94), anti-phospho-ERK(E-4) (#sc-7383), anti-RB(C-15) (#sc-50), anti-
XPO1/CRM1 (H-300) (#sc-5595), anti-β-Actin (#sc-1615). From BD Bioscience:
anti-p53(CM5) (#554293). From Thermo Fisher: HRP-conjugated anti-mouse
(#A16072). Anti-ERK1 (k-23) (#sc-94) and anti-β-Actin (#sc-1615) were diluted
1:1000 in 5% BSA+ TBST 0,1%, all other antibodies were diluted 1:500 in 5%
BSA+ TBST 0,1%, incubation was performed at 4 °C overnight. For image analysis
of western blots, the intensities of individual bands in western blots were analyzed
using Fiji ImageJ densitometry software (version 1.51j). The levels of the proteins
were expressed relative to the loading controls (Actin). Phosphorylation levels of
proteins were expressed as a relative measure compared to that of the total protein
and their respective loading controls (Actin).
Eµ-Myc/Eµ-TCL1 transgenic and BCL1/Eµ-TCL1 transplantation mouse mod-
els. Ethics oversight. We have complied with all relevant ethical regulations, all
animal experiments were performed with the approval of the respective govern-
mental authorities and local animal experimental ethics committees in each
institution. The TCL1 serial transplant mouse model was performed according to
protocols approved by the state government of Baden-Wuerttemberg, following the
animal welfare guidelines (Registration 1124 and 1128), and was approved by the
Ulm University animal experimental ethics committee. The BCL1 syngeneic
transplant model, Eµ-Myc, and Eµ-TCL1 mouse model experiments were con-
ducted under the Home Office licenses PPL30/2964 and P4D9C89EA following
approval by local ethical committees, reporting to the Home Office Animal Welfare
Ethical Review Board (AWERB) at the University of Southampton. Animals were
maintained and bred in a pathogen-free environment (SPF IVC barrier) with a 14/
10 day and night cycle, the temperature at 21 °C and humidity at 55%, as well as
water and food ad libitum.
BCL1 syngeneic transplant model to validate induction of EMT-like networks in
lymphoma. To validate the potential for induction of an EMT-like program and
corresponding dynamics in B cell lymphoma cells, we used a syngeneic BCL1
tumor transplant model. For this 1 × 105 BCL1 tumor cells were inoculated IV into
Balb/c mice and spleens harvested at defined periods of time (day 7 (n= 12), 14
(n= 6), 17 (n= 6), and 21 (n= 6) alongside naive tumor-free mice (n= 4).
Spleens were snap-frozen and then sectioned to provide material from which to
extract RNA. Total RNA was isolated, assessed for purity using NanoDrop at 260/
280 nm and the Bioanalyser. Samples with RIN scores >7 were taken forward and
subjected to RNA sequencing (EA2).
Eµ-TCL1 serial transplant mouse model to assess EMT-like plasticity in
lymphoma. The Eµ-TCL1 tumors prior to the start of the experiment were
transferred and expanded once in syngeneic C57BL6/J mice. For serial transfers, 10
million splenic tumor cells were transplanted by intravenous injection and the
animals were sacrificed when the mice appeared critically sick, a surrogate
endpoint that was defined based on scoring for disease severity including WBC
count, changes in mobility, signs of suffering, as approved by the local animal
experimental ethics committee. The tumor cells were purified with ficoll and only
tumors with more than 90% CD5+ CD19+ CLL cells were used for serial transfers
and analyses. Three rounds of serial transfers were performed and the tumors were
isolated from the spleen. The EMT markers Vimentin (Vim), Cadherin-1 (Cdh1),
and corresponding transcription factors Zeb1 and Snai1 were measured using
qPCR on tumors isolated from the different serial transfers.
Eµ-Myc/Eµ-TCL1 mouse model and proteome profiling to validate GI-specific
networks and associated inhibition of EMT-like networks. Mass spectrometry (MS)
proteomics analyses of Eμ-Myc and Eμ-TCL1 tumors were performed as
described91 and submitted to GSEA. Spontaneous tumors from female Eμ-Myc
[C57BL/6J-TgN(Ighmyc)22Bri/J] hemizygous and Eμ-TCL1 [C57BL/6J-
TgN(IghTCL1)22Bri/J] hemizygous mice were compared with wild-type controls
aged 6 weeks and 200 days, in addition to the pre-terminal model, controls taken at
6 weeks of age. B cells were isolated from spleens by magnetic isolation kit
(Miltenyi Biotech, Bergisch Gladbach, Germany) and snap-frozen. Samples were
pooled with four tumors from each model assigned to two pools of two tumors and
non-tumor pools of six samples, to be accommodated in a single eight-plex. Snap
frozen cell pellets were lysed in 0.5 M TEAB with 0.05% SDS, with 100 μg of
protein lysate per pool TCEP-reduced, MMTS-alkylated, trypsin digested, and
labeled with isobaric tags for relative and absolute quantitation (iTRAQ) 8-plex
according to the manufactures instructions (ABSciex, Framingham, MA). Labeled
peptides were combined and pre-fractionated using a 90-min high-pH reverse-
phase C8 fractionation (2–30% organic) collecting 69 peak-dependent fractions.
Each fraction was analyzed by LC–MS/MS (Dionex Ultimate 3000 and Orbitrap
Elite (Thermo Scientific)) over 200 h of MS time using top 12 data-dependent
acquisition and 120,000 resolution with reporter ions captured with HCD at 35 keV
at 15,000 resolution. Raw data were analyzed by Proteome Discoverer 1.4.1.14 with
SequestHT 1.1.1.11 and Percolator modules searched against the mouse UniProt
Swissprot and trembl databases (downloaded 01/15). The raw data and processed
outputs are available at https://www.ebi.ac.uk/pride/archive/projects/PXD004608.
Relative expression was assigned from iTRAQ reporter regions and was median
normalized and quality-adjusted using spiquetool.com. Log2 (ratios) were
generated describing each tumor sample pool relative to the two WT control pools,
in addition to the 6-week pre-terminal model controls relative to the 6-week WT
control. A value summarizing all 4 log2 (ratios) for each tumor model was also used
(mean/(SD+ 1)). Lists of gene names and corresponding log2 (ratios) and
summary values for all 8270 proteins were analyzed by GSEA 3.0 using the GSEA-
preranked approach due to a non-standard data format enriching for the MSigDB
H and C2 gene sets. All default settings were used.
Radiation-induced DNA damage. The human B cell lines, MEC1, MEC2, JVM2,
JVM3, LCL-WEI, EHEB, and Granta were purchased from the German Collection
of Microorganisms and Cell culture (Deutsche Sammlung von Mikroorganismen
und Zellkulturen, DSMZ) with the certificate from the vendor and were addi-
tionally authenticated through sequencing by Multiplexion GmbH. Cell lines were
cultured in RPMI medium with 10% FCS and 1% L-glutamine/were maintained in
IMDM medium with 10% FCS and 1% L-glutamine. All cells were tested for
mycoplasma contamination monthly. For induction of DNA damage, the cells were
irradiated with 5 Gy γ-irradiation. The cells were collected 4, 8, 16, 24, and 48 h
after ionizing irradiation with 5 Gy, and expression changes in miR-200c, TP53,
TP63, ATM, ZEB1, and TWIST1 were analyzed for individual time points and in
comparison to the corresponding nonirradiated sample.
Assessment on AID induced genomic instability. Cell culture. BL2 cell line was
obtained from the German Collection of Microorganisms and Cell culture (ACC
625. Deutsche Sammlung von Mikroorganismen und Zellkulturen, DSMZ). BL2
AICDA- cells were kindly provided by Claude-Agnes Reynaud (INSERM U1151,
Paris) and were described previously92. Human embryonic kidney HEK293T were
obtained from the European Collection of Authenticated Cell Cultures (ECACC)
(Culture Collections, Public Health England, Salisbury, UK). Cell lines were
authenticated by DSMZ (https://www.dsmz.de/collection/catalog/human-and-
animal-cell-lines/identity-control) or Public Health England (https://www.phe-
culturecollections.org.uk/media/153328/ccw5704-culture-collections-quality-
policy.pdf). BL2 AICDA- cells were not authenticated. Cells were cultured in RPMI
1640 (BL2) or Dulbecco’s Modified Eagle Medium (HEK293T) (Sigma-Aldrich,
Dorset, UK) supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin,
100 U/ml streptomycins at 37 °C in a humidified atmosphere containing 5% CO2.
All cells were tested for mycoplasma contamination monthly. Lentiviral transfec-
tion: Packaging transfection was performed in HEK293 cells using Lipofectamine®
LTX Reagent (Invitrogen®, Carlsbad, CA, USA) and the following vectors: the
pRSV-Rev packaging, pMDLg packaging, pMD2.G envelope, and pLenti-C-mGFP
vector expressing AICDA (NM_020661) Human Tagged ORF Clone (RC202949L2,
OriGene, Cambridge, UK). Lentivirus-containing medium was harvested 24 or 48 h
post-transfection, filtered through 0.45 μm PES filter, and concentrated using
Retro-X Concentrator (Clontech, Takara Bio, USA). After overnight incubation at
+4 °C, the virus-containing mixture was centrifuged for 45 min at 500g and the
pellet was resuspended with the medium in 1:10 of the original volume. Totally,
107 of BL2 AICDA- or HEK 293T cells were then exposed to a virus-containing
medium for 24 h. Infection efficiency was then determined by flow cytometry as a
percentage of GFP+ cells. AID-GFP cells were then FACS sorted using BD
FACSAria II Cell Sorter (BD Biosciences, Wokingham, UK). Immunofluorescence:
For immunofluorescence staining, cells were harvested and cytospun onto
microscope slides. Slides were fixed in −20 °C methanol and washed in TBS/0.05%
Tween. Primary mouse anti-yH2AX (ab26350, Abcam, Cambridge, UK) antibody,
diluted 1:500 in TBS/0.1% BSA, was then applied for 1 h at room temperature.
After three washing steps with TBS/0.05%Tween, slides were stained with sec-
ondary anti-mouse Alexa Fluor 594 (ab150116, Abcam, Cambridge, UK), diluted
1:500, for 1 h at room temperature.
Following three times with TBS/0.05% Tween. Nuclei were counterstained with
DAPI and slides were mounted in ProLong Gold Antifade Reagent (Invitrogen,
Life Technologies, Paisley, UK). Images were taken using Nikon Ci-L upright
fluorescence microscope and Nikon NIS Elements AR software (Ver4.30.01, 64-bit
edition). Assessment of y-H2AX was used as a universal marker of DNA damage,
including DNA double-strand breaks93. Western blot: Total protein lysates were
mixed with NuPAGE® LDS Sample Buffer (Thermo Fisher Scientific, Paisley, UK),
and then 10 µg of protein were resolved on precast 4–12% Bis–Tris Protein Gel
(Thermo Fisher Scientific, Paisley UK). Proteins were transferred by wet transfer
onto Immobilon-P Membrane PVDF membrane (Merck Millipore, Billerica,
Massachusetts, USA), blocked with 5% non-fat skim milk in TBS, and then the
membrane was incubated with appropriately diluted primary antibodies for one
hour at room temperature in TBS/0.1% Tween. After three washing steps,
membranes were incubated with HRP-conjugated anti-mouse antibody (1:2000,
A16072, Thermo Fisher, Paisley, UK). After three washing steps, membrane
chemiluminescence was analyzed by Amersham ECL Prime Western Blotting
Detection Reagent (GE Healthcare®, Little Chalfont, UK) and ChemiDoc imaging
system (BioRad, Hemel Hempstead, UK). The following primary antibodies were
used: mouse anti-y-H2AX [9F3] (1:1500, ab26350, Abcam, Cambridge, UK),
mouse monoclonal [6C5] to GAPDH (1:3000, ab8245, Abcam, Cambridge, UK).
Sister chromatid exchange assay: we used the sister chromatid exchange (SCE)
assay to assess cellular genotoxicity and ongoing mutagenesis94,95. Cells were
cultured in DMEM containing 10 µM 5-bromo-2′-deoxyuridine BrdU (ab142567
Abcam, Cambridge, UK) for two cell divisions cycles. After 4 h treatment with
Colcemid (0.02 μg/mL, 10295892001, Sigma-Aldrich, Gillingham, UK), cells were
incubated with prewarmed 75 mM KCl solution for 20 min at 37 °C. Then, cells
were spun down and fixed using Carnoy’s fixative (methanol: glacial acetic acid).
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Mitotic cells were dropped on pre-chilled microscope slides and left to dry in the
dark at room temperature. Slides were immersed in acridine orange (A1301,
Thermo Fisher Scientific, Paisley, UK) for 5 min, mounted in 2× SSC buffer, and
covered with a coverslip. Images of chromosome spreads were obtained using a
Nikon Ci-L upright fluorescence microscope and Nikon NIS Elements AR software
(Ver4.30.01, 64-bit edition). Sister chromatid exchanges were quantified
microscopically from at least five random fields containing at least 20 metaphase
spreads. Alkaline Single Cell Electrophoresis (Comet) assay: Single Cell
Electrophoresis was performed using CometAssay Kit (4250-050-K, Trevigen, AMS
Biotechnology, Abingdon, UK) as per manufacturer’s instructions. Briefly, 105 cells
were harvested by centrifugation and then resuspended in 1X PBS, mixed with
0.5% low melting agarose, and plated onto comet slides pre-coated with normal
melting point agarose. Subsequently, slides were immersed in comet lysis solution
for one hour at 4 °C. Slides were then further treated with alkaline solution (NaOH
pH 13, 200 mM EDTA in H2O) submerging in an electrophoresis tank. Alkaline
electrophoresis was performed for 30–60 min at 21 V (300 mA), Nuclei and “comet
tails” were subsequently stained with SYBR® Gold stain (Thermo Fisher Scientific,
Paisley, UK). Slides were visualized using fluorescence microscopy, and % of tail
DNA on per cell basis was determined using an open-source Cell Profiler (https://
cellprofiler.org/) software equipped with the Comet Assay analysis module (https://
cellprofiler-examples.s3.amazonaws.com/ExampleCometAssay.zip). Triplicate
slides were processed per each AICDA-related condition with at least 70 comets
analyzed per each condition.
Telomere length analysis. The telomere length measurement was carried out
using a qPCR–based technique96. The primers used to amplify telomere and single-
copy genes (SCG) were tel1b, tel2b, and HBG3, HBG4, respectively96. The absolute
telomere length was obtained by using synthetic oligonucleotide standards for
telomere (84 bp) and SCG (81 bp) PCR. Briefly, a tenfold dilution of the telomere
and SCG standard was prepared and the number of DNA molecules in each
standard was calculated as described97. Twelve nanograms of DNA was used per
reaction (total volume of 10 µl) in triplicates for the telomere and SCG PCRs and
amplified using Qiagen quantitect SYBR green in 384-well plates and analyzed
using 7900HT fast real-time PCR system (Applied Biosystems). Six telomere length
controls with known telomere length, analyzed using terminal restriction fragment
length analysis (TRF) were included in every plate to detect variations. The qPCR
technique was validated by TRF length analysis and Southern hybridization.
Totally, 6 µg of non-degraded DNA was digested overnight using Hinf I and Rsa I
and resolved on a 0.8% agarose gel. In-gel hybridization was carried out by drying
the gel and hybridizing with a telomere-specific probe, end-labeled with 32P. The
mean telomere length was analyzed from the autoradiograph. A correlation of
R2= 0.8516 was obtained upon a comparison of telomere length measured using
qPCR and TRF, in a control sample set (n= 18). The TRF value of telomere length
for each sample was calculated from the linear regression of qPCR vs. TRF.
RRBS and methylation analysis. Genomic DNA from n= 182 matched
CLL8 samples was used to produce RRBS libraries. They were generated by
digesting genomic DNA with MspI to enrich for CpG-rich fragments and then
ligated to barcoded TruSeq adapters (Illumina) to allow immediate subsequent
pooling. It was followed by bisulfite conversion and PCR, as previously described98.
Libraries were sequenced and aligned to the bisulfite-converted hg19 reference
genome using Bismark (RRID: SCR_005604) v0.15.099.
Methylation analysis. Only CpGs with ten or more reads were included in the
analysis. Promoters were defined as the regions encompassing 2 kb upstream and
downstream of the transcription start site of UCSC genes. Promoters or genes with
at least five covered CpGs were included in the analysis. Promoter or gene
methylation was calculated by the average methylation levels of all the CpGs inside.
Survival analysis. CLL8 and REACH clinical trial data were analyzed on an
intention-to-treat basis (eligible subjects were analyzed as randomized).
Progression-free survival (PFS) was defined as the time from randomization to
disease progression or death, overall survival (OS) was defined as the time between
randomization and death. PFS and OS were estimated by the Kaplan–Meier
method, and differences between groups were assessed using two-sided non-stra-
tified log-rank tests. In addition, hazard ratios (HR) and 95% confidence intervals
were calculated using Cox regression modeling. With regard to OS and PFS
multivariable Cox proportional hazards, regression models were used to assess the
independent prognostic value of identified major subtypes (GI, (I)GI, EMT-L, (I)
EMT-L) in CLL8 and REACH. Additional prognostic factors in the models were
treatment, TP53 mutation, IGHV mutation, 17p deletion, 11q deletion, trisomy
12q, and 13q deletion.
Statistical software. Statistical analysis was performed with R version 3.3.3 and
3.4.1, with R package survival, version 2.41-2; SPSS version 24–26 (IBM, NYC,
NY); Prism software version 6.0 h (GraphPad), MATLAB 2018b and BRB-
ArrayTools Version 4.2.1–4.6.1.
Reporting summary. Further information on experimental design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
Complete data sets are available: For GEP at Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/; GEO accession number: GSE58211 (REACH only);
GSE126595 (full clinical data set); GSE126699 (including functional data). For SNP-
Microarray raw data at Gene Expression Omnibus (GEO accession number: GSE36908
(CLL8 treatment-naive) and GSE83566 (relapsed)). CLL8 WES data are deposited in
dbGaP under accession code phs000922.v1.p1. CLL8 RRBS sequencing data are available
from the NCBI (GEO accession number: GSE143673). The proteome profiling raw data
and processed outputs are available at https://www.ebi.ac.uk/pride/archive/projects/
PXD004608. All other relevant data supporting the key findings of this study are
available within the article, its supplementary information, source data files, or from the
corresponding first author upon reasonable request. A reporting summary for this article
is available as a supplementary information file. Source data are provided with this paper.
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